Puretech Health : resTORbio Files Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES OR IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

PureTech's resTORbio Files Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

PureTech Health plc (LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, is pleased to note that resTORbio, Inc., an affiliate of PureTech Health, today announced that it has previously confidentially submitted a draft registration statement on Form S-1 with the United States Securities and Exchange Commission relating to the proposed initial public offering of its common stock. The announcement is being issued in accordance with Rule 135 under the U.S. Securities Act of 1933, as amended.

The full text of the announcement from resTORbio is as follows:

resTORbio Files Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

Boston, Massachusetts, December 5, 2017 - resTORbio, Inc. today announced that it has previously confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the 'SEC') relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is expected to commence after the SEC completes its review process, subject to market and other conditions.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended ('Securities Act'). This announcement is being issued in accordance with Rule 135 under the Securities Act.

This announcement does not constitute, or form part of, any offer or invitation to sell, allot or issue, or any solicitation of any offer to purchase or subscribe for, any securities, nor shall it (or any part of it) or the fact of its distribution form the basis of, or be relied upon in connection with, or act as any inducement to enter into, any contract or commitment for securities.

Shareholders and potential investors should note this announcement does not constitute a recommendation concerning the proposed initial public offering by resTORbio (the 'Offering'). The price and value of securities and any income from them can go down as well as up. Past performance is not a guide to future performance. Information in this announcement or any of the documents relating to the Offering cannot be relied upon as a guide to future performance. There is no guarantee that the Offering will occur and you should not base your financial decisions in relation to the Offering at this stage. Potential investors should consult a professional advisor as to the suitability of the Offering for the entity or person concerned.

This announcement does not contain or constitute an offer of, or solicitation of an offer to buy or subscribe for the securities referred to herein to any person in any jurisdiction, including the United States, Australia, Canada, Japan, New Zealand, or the Republic of South Africa or in any jurisdiction to whom or in which such offer or solicitation is unlawful.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.